LSD
Also known as: Acid, Lysergic Acid Diethylamide, Lucy
LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first made by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors and changes perception, mood and thinking for 8 to 12 hours. In the 1950s and 60s it was studied for alcoholism and anxiety bef...
Applications
5
Clinical Trials
4
Evidence Tier
moderate
Duration
8-12 hours peak effects, with subtle aftereffects lasting up to 24 hours
Overview
LSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first made by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors and changes perception, mood and thinking for 8 to 12 hours. In the 1950s and 60s it was studied for alcoholism and anxiety before research stopped under prohibition. Modern trials have returned: Definium Therapeutics (formerly MindMed) reported positive Phase 3 results for its LSD drug candidate, DT120, in major depression (Emerge, June 2026) and generalized anxiety disorder (Voyage, August 2026), where it reduced symptoms more than placebo. As of October 2026, LSD is not FDA-approved; the company has said it plans to apply in 2027. A 2025 phase 2a trial of repeated low doses of LSD for adult ADHD did not beat placebo on its primary outcome. Earlier work at the University of Basel studied LSD-assisted therapy for anxiety in people with life-threatening illness, and neuroimaging studies at Imperial College London showed how LSD changes communication between brain networks.
Traditional Use
No traditional use; LSD is a modern synthetic compound discovered in 1938. Used extensively in psychiatric research and psychotherapy from 1950s-1970s.
Therapeutic Applications
Clinical Trials
DT120 (LSD) for Generalized Anxiety Disorder (Voyage)
Completed August 2026 - Met Primary EndpointDT120 (LSD) for Major Depressive Disorder (Emerge)
Completed June 2026 - Met Primary EndpointLow-Dose LSD for Adult ADHD
Completed 2025 - Negative Primary EndpointLSD for Anxiety in Life-Threatening Illness
Completed - Positive ResultsRisks & Contraindications
Potential Risks
- •Prolonged anxiety or panic during experience
- •Potential triggering of latent psychosis
- •Challenging psychological experiences
- •Increased heart rate and blood pressure
- •Rare persistent perceptual changes (HPPD)
- •Risk of accidents due to altered perception
Contraindications
- Personal or family history of psychotic disorders
- Severe cardiovascular disease
- Pregnancy and breastfeeding
- Uncontrolled psychiatric conditions
- Concurrent use with lithium (seizure risk)
Safety screening
Psychedelics are not safe for everyone. Talk with a licensed clinician first, especially if any of these apply to you:
- Antidepressants such as SSRIs and SNRIs, and other medicines that raise serotonin (tramadol, for example): they can blunt the effect of psychedelics, and with some substances, such as MDMA and ayahuasca, raise the risk of serotonin syndrome.
- Lithium: seizures have been reported when lithium is combined with classic psychedelics such as psilocybin and LSD.
- MAOIs, including the MAOIs in ayahuasca: dangerous interactions with many medicines, other substances and some foods.
- Heart disease, high blood pressure, or a heart rhythm problem such as long QT syndrome.
- A personal or family history of psychosis, schizophrenia or bipolar disorder.
- Pregnancy or breastfeeding.
Never stop or change a prescribed medicine without your prescriber.
Gabriel doesn't give psychedelic dosing and doesn't help anyone obtain psychedelics. This page explains research and risks; it is not medical advice.
If you're in crisis, call or text 988 (Suicide and Crisis Lifeline). For a medical emergency, call 911.
Legal Status
Legal status as of October 2026. Laws change; check the current law where you live. This is not legal advice.
United States
Schedule I federally. Not FDA-approved as of October 2026; available only in clinical trials.
International
Schedule I or equivalent in most countries under UN drug conventions. Research permitted with special licenses.
Key Researchers
Key Studies
- 1Gasser et al. - Safety and efficacy of LSD-assisted psychotherapy for anxiety associated with life-threatening diseases (2014)
- 2Carhart-Harris et al. - Neural correlates of the LSD experience revealed by multimodal neuroimaging (2016)
- 3Dolder et al. - LSD acutely impairs fear recognition and enhances emotional empathy and sociality (2016)
Quick Facts
Questions? Ask Gabriel
Gabriel can help you find and book licensed clinicians who offer ketamine or esketamine treatment. Gabriel doesn't prescribe ketamine.
Ask GabrielRelated Substances
Psilocybin
Psilocybin is a naturally occurring psychedelic compound found in more than 200 species of mushrooms. In the body it converts to psilocin, which activates serotonin 5-HT2A receptors in the brain, changing perception, mood and thinking for several hours. In clinical trials, psilocybin given with psychological support has reduced depression symptoms within days, with effects lasting weeks to months for some participants. Compass Pathways has run two Phase 3 trials of COMP360, a synthetic psilocybin, for treatment-resistant depression: in COMP005 (results June 2025) it beat placebo by 3.6 points on the MADRS depression scale at week 6, and in COMP006 (results February 2026) it beat a very low comparison dose by 3.8 points. As of October 2026, psilocybin is not FDA-approved; Compass says it is completing its application to FDA. Researchers at Johns Hopkins, NYU Langone, Imperial College London and other centers have also studied psilocybin for anxiety and depression in people with cancer, alcohol and tobacco use disorders, and obsessive-compulsive disorder. Trials pair it with preparation and follow-up sessions with trained therapists, and screen people carefully before treatment.
DMT / 5-MeO-DMT
DMT (N,N-dimethyltryptamine) and its close relative 5-MeO-DMT are among the most potent psychedelics known, with intense but short effects. N,N-DMT is found in many plants and is the active compound in ayahuasca; inhaled, its effects last about 15 to 30 minutes and often include vivid visual patterns and a strong sense of meeting other beings. 5-MeO-DMT, found in some plants and in the venom of the Sonoran Desert toad (Incilius alvarius), tends to produce a loss of the sense of self rather than visual imagery. In a small phase 2a trial led at Imperial College London and published in Nature Medicine in February 2026, a single IV dose of DMT (SPL026) given with psychological support reduced depression scores more than placebo at two weeks. In a 2025 Phase 2b trial in 193 people with treatment-resistant depression, Beckley Psytech's intranasal 5-MeO-DMT (BPL-003) reduced depression scores more than a very low comparison dose, with no serious adverse events; a Phase 3 program was planned for 2026. Neither is FDA-approved. The trials use synthetic compounds. Toad-derived 5-MeO-DMT has no verified history of traditional indigenous use (modern toad ceremonies date from about 2015), and collecting the venom harms wild toad populations.